SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049135
Filing Date
2024-04-26
Accepted
2024-04-26 16:13:01
Documents
7
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A onct_proxy_2024.htm DEF 14A 876061
2 GRAPHIC img242103616_0.jpg GRAPHIC 102614
3 GRAPHIC img242103616_1.jpg GRAPHIC 102719
4 GRAPHIC img242103616_2.jpg GRAPHIC 724324
5 GRAPHIC img242103616_3.jpg GRAPHIC 730619
6 GRAPHIC img242103616_4.jpg GRAPHIC 1205584
7 GRAPHIC img242103616_5.jpg GRAPHIC 60865
  Complete submission text file 0000950170-24-049135.txt   4684484
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

IRS No.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50549 | Film No.: 24883890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)